Wei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wei Zhang has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Hao Helen Hou
Synthetic Molecule Pharmaceutical Sciences, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
6 shared publicationsKarthik Nagapudi
Synthetic Molecule Pharmaceutical Sciences, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
3 shared publicationsPo-Chang Chiang
Synthetic Molecule Pharmaceutical Sciences, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
3 shared publicationsBenjamin W. Weitz
Genentech Inc, Synthet Mol Pharmaceut Sci, 1 DNA Way, South San Francisco, CA 94080 USA
2 shared publicationsCheng W. Chiang
Synthetic Molecule Pharmaceutical Sciences, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
2 shared publicationsJia Liu
Synthetic Molecule Pharmaceutical Sciences, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States
2 shared publications
Latest Publications
- 10 June 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (7) , 3782-3792
Solid-State Evaluation of a Newly Emerged Polymorph for Early-Stage Pharmaceutical Development
This work presents the solid-state evaluation of a new polymorph (Form M) discovered during the early-stage pharmaceutical development of a new chemical entity GDC-6599. Form screening and active pharmaceutical ingredient (API) crystallization development identified Form A of GDC-6599 as the experimentally most stable polymorph, although more stable polymorphs were predicted by crystal structure prediction (CSP). Later, a new polymorph, Form M, was discovered in the crystallization of a kilogram-scale API batch. The powder X-ray diffraction (PXRD) pattern of Form M was consistent with the calculated pattern of the predicted most stable polymorph (Rank 1) by CSP. Form A and Form M were subsequently speculated as enantiotropic polymorphs according to their melting temperatures and enthalpies. Slurry competition (SC) experimentally confirmed Form M as the more stable polymorph at temperatures relevant to pharmaceutical development. To support API manufacturing, a quantitative PXRD method was successfully developed for controlling the Form A percentage during the API crystallization process. To understand the impact of Form M on the drug product performance, pharmaceutical and biopharmaceutical evaluations were carried out. The intrinsic solubility of Form M was found to be 56% of the intrinsic solubility of Form A, consistent with their calculated solubility ratio based on the Gibbs free energy difference predicted by CSP. Biopharmaceutical assessment further suggested that the observed solubility reduction would not impact the biopharmaceutical performance of GDC-6599 at doses relevant for the proposed clinical studies, providing form selection flexibility for clinical formulation development. Accordingly, Form M was recommended for future API manufacturing and solid dosage form development. Meanwhile, Form A was confirmed to be physically stable in a suspension formulation for extemporaneous preparation and was recommended to support the early cohorts of Phase I clinical studies.
- 10 June 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (7) , 3782-3792
Solid-State Evaluation of a Newly Emerged Polymorph for Early-Stage Pharmaceutical Development
This work presents the solid-state evaluation of a new polymorph (Form M) discovered during the early-stage pharmaceutical development of a new chemical entity GDC-6599. Form screening and active pharmaceutical ingredient (API) crystallization development identified Form A of GDC-6599 as the experimentally most stable polymorph, although more stable polymorphs were predicted by crystal structure prediction (CSP). Later, a new polymorph, Form M, was discovered in the crystallization of a kilogram-scale API batch. The powder X-ray diffraction (PXRD) pattern of Form M was consistent with the calculated pattern of the predicted most stable polymorph (Rank 1) by CSP. Form A and Form M were subsequently speculated as enantiotropic polymorphs according to their melting temperatures and enthalpies. Slurry competition (SC) experimentally confirmed Form M as the more stable polymorph at temperatures relevant to pharmaceutical development. To support API manufacturing, a quantitative PXRD method was successfully developed for controlling the Form A percentage during the API crystallization process. To understand the impact of Form M on the drug product performance, pharmaceutical and biopharmaceutical evaluations were carried out. The intrinsic solubility of Form M was found to be 56% of the intrinsic solubility of Form A, consistent with their calculated solubility ratio based on the Gibbs free energy difference predicted by CSP. Biopharmaceutical assessment further suggested that the observed solubility reduction would not impact the biopharmaceutical performance of GDC-6599 at doses relevant for the proposed clinical studies, providing form selection flexibility for clinical formulation development. Accordingly, Form M was recommended for future API manufacturing and solid dosage form development. Meanwhile, Form A was confirmed to be physically stable in a suspension formulation for extemporaneous preparation and was recommended to support the early cohorts of Phase I clinical studies.
- 5 October 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (1) , 304-312
Investigating the effects of formulation variables on the disintegration of spray dried amorphous solid dispersion tablets
- 5 October 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (1) , 304-312
Investigating the effects of formulation variables on the disintegration of spray dried amorphous solid dispersion tablets
- 2 February 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 653, 123868
Development of an extemporaneous preparation formulation using a simple and non-solubilizing matrix for first in human clinical study
- 2 February 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 653, 123868
Development of an extemporaneous preparation formulation using a simple and non-solubilizing matrix for first in human clinical study
- 4 October 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (11) , 5888-5900
Comparative Evaluation of Particle Size Reduction, Salt Formation, and Amorphous Formulation on the Biopharmaceutical Performance of a Weak Base Drug Candidate
Various approaches have been developed to enhance the solubility or dissolution rate for the delivery of poorly water-soluble molecules. In this work, guided by an in silico solubility sensitivity analysis for oral absorption, a comparative assessment of the biopharmaceutical performance of a jet-milled free base, a tosylate salt, and a 50:50 (w/w) amorphous solid dispersion (ASD) with hydroxypropyl methylcellulose acetate succinate (HPMCAS) of a weak base drug candidate, GDC-3280, was conducted. Successful particle size reduction without amorphization or form change was confirmed for the jet-milled free base. The potential of solubility enhancement and desupersaturation risk were identified for tosylate salt and ASD formulation by measurements of tosylate salt solubility product constant (K-sp) and amorphous solubility of GDC-3280. In vitro dissolution testing demonstrated dissolution rate improvement for the jet-milled free base when compared with the unmilled free base and confirmed solubility enhancement followed by desupersaturation for GDC-3280 tosylate salt and ASD formulation. A crystallization inhibitor, hydroxypropyl methylcellulose (HPMC), was found to slow down the desupersaturation of tosylate salt solution, providing general insights for the development of pharmaceutical salts with disproportionation risks. Finally, a pharmacokinetic study in dogs showed that the in vivo exposure increased by 1.7- to 2-fold for the tosylate salt and ASD formulation compared with the jet-milled free base, consistent with the in silico solubility sensitivity analysis for the fraction of drug absorbed. Overall, this work provides insights into the evaluation of multiple formulation approaches for enhancing the biopharmaceutical performance of poorly water-soluble drugs.
- 4 October 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (11) , 5888-5900
Comparative Evaluation of Particle Size Reduction, Salt Formation, and Amorphous Formulation on the Biopharmaceutical Performance of a Weak Base Drug Candidate
Various approaches have been developed to enhance the solubility or dissolution rate for the delivery of poorly water-soluble molecules. In this work, guided by an in silico solubility sensitivity analysis for oral absorption, a comparative assessment of the biopharmaceutical performance of a jet-milled free base, a tosylate salt, and a 50:50 (w/w) amorphous solid dispersion (ASD) with hydroxypropyl methylcellulose acetate succinate (HPMCAS) of a weak base drug candidate, GDC-3280, was conducted. Successful particle size reduction without amorphization or form change was confirmed for the jet-milled free base. The potential of solubility enhancement and desupersaturation risk were identified for tosylate salt and ASD formulation by measurements of tosylate salt solubility product constant (K-sp) and amorphous solubility of GDC-3280. In vitro dissolution testing demonstrated dissolution rate improvement for the jet-milled free base when compared with the unmilled free base and confirmed solubility enhancement followed by desupersaturation for GDC-3280 tosylate salt and ASD formulation. A crystallization inhibitor, hydroxypropyl methylcellulose (HPMC), was found to slow down the desupersaturation of tosylate salt solution, providing general insights for the development of pharmaceutical salts with disproportionation risks. Finally, a pharmacokinetic study in dogs showed that the in vivo exposure increased by 1.7- to 2-fold for the tosylate salt and ASD formulation compared with the jet-milled free base, consistent with the in silico solubility sensitivity analysis for the fraction of drug absorbed. Overall, this work provides insights into the evaluation of multiple formulation approaches for enhancing the biopharmaceutical performance of poorly water-soluble drugs.
- 2 May 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (6) , 2764-2765
Voices in Molecular Pharmaceutics: Meet Dr. Wei Zhang, a Pharmaceutical Scientist Developing Drug Products for Patients
- 2 May 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (6) , 2764-2765
Voices in Molecular Pharmaceutics: Meet Dr. Wei Zhang, a Pharmaceutical Scientist Developing Drug Products for Patients
- 3 April 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (5) , 2452-2464
Development of an Amorphous Solid Dispersion Formulation for Mitigating Mechanical Instability of Crystalline Form and Improving Bioavailability for Early Phase Clinical Studies
In this work, an amorphous solid dispersion (ASD) formulation was systematically developed to simultaneously enhance bioavailability and mitigate the mechanical instability risk of the selected crystalline form of a development drug candidate, GDC-0334. The amorphous solubility advantage calculation was applied to understand the solubility enhancement potential by an amorphous formulation for GDC-0334, which showed 2.7 times theoretical amorphous solubility advantage. This agreed reasonably well with the experimental solubility ratio between amorphous GDC-0334 and its crystalline counterpart (∼2 times) in buffers of a wide pH range. Guided by the amorphous solubility advantage, ASD screening was then carried out, focusing on supersaturation maintenance and dissolution performance. It was found that although the type of polymer carrier did not impact ASD performance, the addition of 5% (w/w) sodium dodecyl sulfate (SDS) significantly improved the GDC-0334 ASD dissolution rate. After ASD composition screening, stability studies were conducted on selected ASD powders and their hypothetical tablet formulations. Excellent stability of the selected ASD prototypes with or without tablet excipients was observed. Subsequently, ASD tablets were prepared, followed by in vitro and in vivo evaluations. Similar to the effect of facilitating the dissolution of ASD powders, the added SDS improved the disintegration and dissolution of ASD tablets. Finally, a dog pharmacokinetic study confirmed 1.8 to 2.5-fold enhancement of exposure by the developed ASD tablet over the GDC-0334 crystalline form, consistent with the amorphous solubility advantage of GDC-0334. A workflow of developing an ASD formulation for actual pharmaceutical application was proposed according to the practice of this work, which could provide potential guidance for ASD formulation development in general for other new chemical entities.
- 3 April 2023
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (5) , 2452-2464
Development of an Amorphous Solid Dispersion Formulation for Mitigating Mechanical Instability of Crystalline Form and Improving Bioavailability for Early Phase Clinical Studies
In this work, an amorphous solid dispersion (ASD) formulation was systematically developed to simultaneously enhance bioavailability and mitigate the mechanical instability risk of the selected crystalline form of a development drug candidate, GDC-0334. The amorphous solubility advantage calculation was applied to understand the solubility enhancement potential by an amorphous formulation for GDC-0334, which showed 2.7 times theoretical amorphous solubility advantage. This agreed reasonably well with the experimental solubility ratio between amorphous GDC-0334 and its crystalline counterpart (∼2 times) in buffers of a wide pH range. Guided by the amorphous solubility advantage, ASD screening was then carried out, focusing on supersaturation maintenance and dissolution performance. It was found that although the type of polymer carrier did not impact ASD performance, the addition of 5% (w/w) sodium dodecyl sulfate (SDS) significantly improved the GDC-0334 ASD dissolution rate. After ASD composition screening, stability studies were conducted on selected ASD powders and their hypothetical tablet formulations. Excellent stability of the selected ASD prototypes with or without tablet excipients was observed. Subsequently, ASD tablets were prepared, followed by in vitro and in vivo evaluations. Similar to the effect of facilitating the dissolution of ASD powders, the added SDS improved the disintegration and dissolution of ASD tablets. Finally, a dog pharmacokinetic study confirmed 1.8 to 2.5-fold enhancement of exposure by the developed ASD tablet over the GDC-0334 crystalline form, consistent with the amorphous solubility advantage of GDC-0334. A workflow of developing an ASD formulation for actual pharmaceutical application was proposed according to the practice of this work, which could provide potential guidance for ASD formulation development in general for other new chemical entities.
- 1 January 2021
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 592, 120087
Impact of polymer type, ASD loading and polymer-drug ratio on ASD tablet disintegration and drug release
- 1 January 2021
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 592, 120087
Impact of polymer type, ASD loading and polymer-drug ratio on ASD tablet disintegration and drug release
- 1 October 2019
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (10) , 3262-3271
Impact of Surfactant and Surfactant-Polymer Interaction on Desupersaturation of Clotrimazole
- 1 October 2019
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (10) , 3262-3271
Impact of Surfactant and Surfactant-Polymer Interaction on Desupersaturation of Clotrimazole